This database contains 61 studies, archived under the term: "cohort studies"
Click here to filter this large number of results.
Influence of social support on cognitive change and mortality in old age: results from the prospective multicentre cohort study AgeCoDe
Eisele, Marion,
Zimmermann, Thomas,
Köhler, Mirjam,
Wiese, Birgitt,
Heser, Kathrin,
Tebarth, Franziska,
Weeg, Dagmar,
Olbrich, Julia,
Pentzek, Michael,
Fuchs, Angela,
Weyerer, Siegfried,
Werle, Jochen,
Leicht, Hanna,
König, Hans-Helmut,
Luppa, Melanie,
Riedel-Heller, Steffi,
Maier, Wolfgang,
Scherer, Martin
Background: Social support has been suggested to positively influence cognition and mortality in old age. However, this suggestion has been questioned due to inconsistent operationalisations of social support among studies and the small number of longitudinal studies available. This study aims to investigate the influence of perceived social support, understood as the emotional component of […]
CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy
Ellis, Ronald J.,
Badiee, Jayraan,
Vaida, Florin,
Letendre, Scott,
Heaton, Robert K.,
Clifford, David,
Collier, Ann C.,
Gelman, Benjamin,
McArthur, Justin,
Morgello, Susan,
McCutchan, J. Allen,
Grant, Igor
Objective: Despite immune recovery in individuals on combination antiretroviral therapy (CART), the frequency of HIV-associated neurocognitive disorders (HANDs) remains high. Immune recovery is typically achieved after initiation of ART from the nadir, or the lowest historical CD4. The present study evaluated the probability of neuropsychological impairment (NPI) and HAND as a function of CD4 nadir […]
Comparative cardiovascular safety of dementia medications: a cross-national study
Fosbøl, Emil L.,
Peterson, Eric D.,
Holm, Ellen,
Gislason, Gunnar H.,
Zhang, Yinghong,
Curtis, Lesley H.,
Køber, Lars,
Iwata, Isao,
Torp-Pedersen, Christian,
Setoguchi, Soko
Objectives: To compare the cardiovascular safety of currently marketed dementia medications in new users in the United States and Denmark.; Design: Retrospective cohort study.; Setting: Nationally representative sample of Medicare beneficiaries from 2006 through 2009 and nationwide Danish administrative registries from 1997 through 2007.; Participants: Individuals treated with a dementia medication aged 65 and older.; […]
Safety and tolerability of galantamine in possible Alzheimer’s disease with or without cerebrovascular disease and vascular dementia in Thai patients
Senanarong, Vorapun,
Poungvarin, Niphon,
Phanthumchinda, Kammant,
Thavichachart, Nuntika,
Chankrachang, Siwaporn,
Praditsuwan, Rungnirund,
Nidhinandana, Samart
The purpose of this study was to explore factors that influence the clinical safety and tolerability associated with galantamine administration in Thai Alzheimer’s disease patients with or without cerebrovascular disease and vascular dementia. This was an analysis of previous study. Tolerability and safety profile were analyzed according to sex, age, body weight, Thai mental state […]
Treatment of Alzheimer’s disease with a cholinesterase inhibitor combined with antioxidants
A formula (formula F) was prepared to counteract oxidative stress (OS) in the brain. The formula contained the most common antioxidants and was intended to: (a) protect proteins, lipids, DNA and proteoglycans from oxidation (carnosine, coenzyme Q(10), vitamin E, vitamin C, beta-carotene, selenium, L-cysteine and ginkgo biloba); (b) reduce homocysteine (HCy) blood levels (vitamins B(6), […]
Validity of the free and cued selective reminding test in predicting dementia: the 3C study
Auriacombe, S.,
Helmer, C.,
Amieva, H.,
Berr, C.,
Dubois, B.,
Dartigues, J. F.
Objective: We assessed the validity of the Free and Cued Selective Reminding Test (FCSRT) in predicting dementia 2 and 5 years after initial evaluation in a population-based cohort over age 65 years participating in the French 3 Cities (3C) study.; Methods: The FCSRT was administered at baseline along with demographics, cognitive and functional scales, and […]
Addenbrooke’s Cognitive Examination validation in Parkinson’s disease
Reyes, M. A.,
Perez-Lloret, S.,
Roldan Gerschcovich, E.,
Martin, M. E.,
Leiguarda, R.,
Merello, M.
Background: There is a clear need for brief, sensitive and specific cognitive screening instruments in Parkinson’s disease (PD).; Objectives: To study Addenbrooke’s Cognitive Examination (ACE) validity for cognitive assessment of PD patient’s using the Mattis Dementia Rating Scale (MDRS) as reference method. A specific scale for cognitive evaluation in PD, in this instance the Scales […]